search
Back to results

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Primary Purpose

EGFRI Induced Acneiform Lesions

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LUT014 Gel (Dose 1)
LUT014 Gel (Dose 2)
Placebo
Sponsored by
Lutris Pharma Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for EGFRI Induced Acneiform Lesions focused on measuring EGFRI, Acneiform, Acneiform lesions, Acneiform rash, EGFRI induced skin toxicities

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosed with mCRC;
  2. Currently being treated with an FDA approved monoclonal antibody EGFRI for the treatment of mCRC, including but not limited to Erbitux® (cetuximab) Injection and Vectibix® (panitumumab) Injection, as directed by the approved labeling;
  3. Grade 2 or Grade 3 non-infected acneiform lesions at the Screening and Baseline;
  4. A reversed score of no more than 44 for the skin-specific questions (first 13 questions) of the FACT-EGFRI-18 HRQoL questionnaire at the Screening and Baseline;
  5. Age ≥18 years at the time of signing the informed consent form (ICF);
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;
  7. Expected life expectancy greater than 3 months;
  8. Subject can understand and sign the ICF, can communicate with the Investigator, can understand and comply with the requirements of the protocol, and can apply the study drug by himself/herself or has a care giver that can apply the drug;
  9. Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline (Day 0);

Exclusion Criteria:

  1. Active infection within the treatment area or in other body areas that requires initiation of systemic antibiotics ;
  2. Significant skin disease other than EGFRI induced acneiform lesions within the same body areas planned for study drug application;
  3. Has a beard that would interfere with administration of study drug and assessment of study endpoints (scoring of lesions);
  4. Any cancer other than mCRC within 3 years of Screening, except for carcinoma in situ of the cervix;
  5. Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study;
  6. Clinically relevant serious co-morbid medical conditions including, but not limited to, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, active central nervous system (CNS) disease uncontrolled by standard of care, known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements;
  7. Pregnant or lactating;
  8. Treatment with an EGFRI other than the FDA approved monoclonal antibody EGFRI for the treatment of mCRC within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer;
  9. Treatment with a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), Braftovi® (encorafenib), and Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer. Patients whose mCRC is being treated with a monoclonal antibody EGFRI in combination with a B-Raf inhibitor, such as Erbitux® (cetuximab) Injection in combination with Braftovi® (encorafenib) Capsules, will not be eligible to participate in this trial;
  10. Treatment with a systemic corticosteroid 14 days prior to Baseline or treatment with a topical corticosteroid to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0). Patients receiving systemic corticosteroids for 24 hours or less only at the time of chemotherapy infusions (for the prevention or treatment of chemotherapy-induced nausea and vomiting) will be allowed to enroll into this study;
  11. Treatment with a topical antibiotic to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0);
  12. Initiation of treatment with systemic antibiotic(s) < 28 days prior to Baseline (Day 0) or any change in dose or frequency of systemic antibiotic(s) within 28 days prior to Baseline. Patients that undergo a washout from systemic antibiotic(s) will be allowed to participate in this trial as long as no systemic antibiotics are taken within 7 days prior to Baseline and they meet all other eligibility criteria;
  13. Treatment with any other topical medication applied to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0).
  14. Treatment with an oral retinoid within 30 days or 5 half-lives of the drug prior to Baseline (Day 0), whichever is longer. Patients that undergo a washout from oral retinoids will be allowed to participate
  15. Treatment with another investigational drug within 30 days or 5 half-lives of drug prior to Screening, whichever is longer;
  16. Known hypersensitivity to the inactive ingredients of the study drug (active or placebo).

Sites / Locations

  • Innovative Clinical Research InstituteRecruiting
  • UCLARecruiting
  • Miami Dermatology & Laser ResearchRecruiting
  • Miami Dermatology and Laser InstituteRecruiting
  • Moffit Cancer CenterRecruiting
  • Appalachian Regional HealthcareRecruiting
  • Willis-Knighton Cancer CenterRecruiting
  • Dana Farber Cancer InstituteRecruiting
  • Hackensack Meridian HealthRecruiting
  • Memorial Sloane KetteringRecruiting
  • New York Cancer and Blood SpecialistsRecruiting
  • The Christ HospitalRecruiting
  • Fox Chase Cancer CenterRecruiting
  • UPMC Hillman Cancer Center Investigational Drug ServiceRecruiting
  • The University of Texas MD Anderson Cancer CenterRecruiting
  • Providence Regional Cancer Partnership
  • MultiCare Institute for Research and InnovationRecruiting
  • Assuta AshdodRecruiting
  • E. Wolfson Medical CenterRecruiting
  • Shaara Zedek Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

LUT014 Gel (Dose 1)

LUT014 Gel (Dose 2)

Placebo

Arm Description

Outcomes

Primary Outcome Measures

The proportion of subjects in each treatment group who reached treatment success
Treatment success will be defined as an improvement (decrease) of at least one grade in the severity of the acneiform lesions from baseline to Day 28, based on CTCAE V5.0 skin and subcutaneous tissue disorders grading scale OR an improvement (increase) of at least 5 points in the total score for the skin-specific (first 13 questions) of the FACT-EGFRI-18 HRQoL questionnaire, from baseline to Day 28, with the exception of subjects who: their dose of EGFRI was decreased, delayed, or stopped during the RDPBC treatment period initiated treatment with topical or systemic antibiotic(s) for the treatment of their acneiform lesions during the RDPBC treatment period experience an increase in the dose or frequency of the systemic antibiotic(s) relative to Baseline during the RDPBC treatment period are discontinued from study drug (active or placebo) during the RDBPC treatment period due to worsening of their acneiform lesions

Secondary Outcome Measures

Change in the severity of acneiform lesions based on CTCAE grading scale from baseline to Days 7, 14, 21, 28, and 55. For subjects enrolled in the OLE, the change from pre-dose Day 28 to Days 35, 42, 49, 56, and 84 will also be evaluated;
Change in the FACT-EGFRI-18 questionnaire total score for the skin-specific questions from baseline to Days 7, 14, 21, 28, and 55. For subjects enrolled in the OLE, the change from pre-dose Day 28 to Days 35, 42, 49, 56, and 84 will also be evaluated;
Relative change in the FACT-EGFRI-18 HRQoL questionnaire
Relative change in the FACT-EGFRI-18 score for the skin-specific questions from D0 to D7,14,21,28, 55 compared to the maximal possible improvement in the score from D0; and the relative change from D28 to D35,42,49,56,84 compared to the maximal possible improvement in the score from D28 for OLE subjects.
Proportion of subjects whose dose of EGFRI was decreased, delayed, or stopped during the RDPBC and the OLE treatment period
Number of AEs and the number and percentage of subjects with AEs

Full Information

First Posted
February 10, 2021
Last Updated
October 5, 2023
Sponsor
Lutris Pharma Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04759664
Brief Title
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 12, 2021 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lutris Pharma Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
EGFRI Induced Acneiform Lesions
Keywords
EGFRI, Acneiform, Acneiform lesions, Acneiform rash, EGFRI induced skin toxicities

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
117 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LUT014 Gel (Dose 1)
Arm Type
Experimental
Arm Title
LUT014 Gel (Dose 2)
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
LUT014 Gel (Dose 1)
Intervention Description
Topical gel
Intervention Type
Drug
Intervention Name(s)
LUT014 Gel (Dose 2)
Intervention Description
Topical gel
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
LUT014 matching placebo topical gel
Primary Outcome Measure Information:
Title
The proportion of subjects in each treatment group who reached treatment success
Description
Treatment success will be defined as an improvement (decrease) of at least one grade in the severity of the acneiform lesions from baseline to Day 28, based on CTCAE V5.0 skin and subcutaneous tissue disorders grading scale OR an improvement (increase) of at least 5 points in the total score for the skin-specific (first 13 questions) of the FACT-EGFRI-18 HRQoL questionnaire, from baseline to Day 28, with the exception of subjects who: their dose of EGFRI was decreased, delayed, or stopped during the RDPBC treatment period initiated treatment with topical or systemic antibiotic(s) for the treatment of their acneiform lesions during the RDPBC treatment period experience an increase in the dose or frequency of the systemic antibiotic(s) relative to Baseline during the RDPBC treatment period are discontinued from study drug (active or placebo) during the RDBPC treatment period due to worsening of their acneiform lesions
Time Frame
Four weeks (28 days)
Secondary Outcome Measure Information:
Title
Change in the severity of acneiform lesions based on CTCAE grading scale from baseline to Days 7, 14, 21, 28, and 55. For subjects enrolled in the OLE, the change from pre-dose Day 28 to Days 35, 42, 49, 56, and 84 will also be evaluated;
Time Frame
8-16 weeks (56-84 days)
Title
Change in the FACT-EGFRI-18 questionnaire total score for the skin-specific questions from baseline to Days 7, 14, 21, 28, and 55. For subjects enrolled in the OLE, the change from pre-dose Day 28 to Days 35, 42, 49, 56, and 84 will also be evaluated;
Time Frame
8 -16 weeks (56-84 days)
Title
Relative change in the FACT-EGFRI-18 HRQoL questionnaire
Description
Relative change in the FACT-EGFRI-18 score for the skin-specific questions from D0 to D7,14,21,28, 55 compared to the maximal possible improvement in the score from D0; and the relative change from D28 to D35,42,49,56,84 compared to the maximal possible improvement in the score from D28 for OLE subjects.
Time Frame
8 weeks (56 days)
Title
Proportion of subjects whose dose of EGFRI was decreased, delayed, or stopped during the RDPBC and the OLE treatment period
Time Frame
4 weeks (28 days)
Title
Number of AEs and the number and percentage of subjects with AEs
Time Frame
8 weeks (6 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with mCRC; Currently being treated with an FDA approved monoclonal antibody EGFRI for the treatment of mCRC, including but not limited to Erbitux® (cetuximab) Injection and Vectibix® (panitumumab) Injection, as directed by the approved labeling; Grade 2 or Grade 3 non-infected acneiform lesions at the Screening and Baseline; A reversed score of no more than 44 for the skin-specific questions (first 13 questions) of the FACT-EGFRI-18 HRQoL questionnaire at the Screening and Baseline; Age ≥18 years at the time of signing the informed consent form (ICF); Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2; Expected life expectancy greater than 3 months; Subject can understand and sign the ICF, can communicate with the Investigator, can understand and comply with the requirements of the protocol, and can apply the study drug by himself/herself or has a care giver that can apply the drug; Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline (Day 0); Exclusion Criteria: Active infection within the treatment area or in other body areas that requires initiation of systemic antibiotics ; Significant skin disease other than EGFRI induced acneiform lesions within the same body areas planned for study drug application; Has a beard that would interfere with administration of study drug and assessment of study endpoints (scoring of lesions); Any cancer other than mCRC within 3 years of Screening, except for carcinoma in situ of the cervix; Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study; Clinically relevant serious co-morbid medical conditions including, but not limited to, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, active central nervous system (CNS) disease uncontrolled by standard of care, known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements; Pregnant or lactating; Treatment with an EGFRI other than the FDA approved monoclonal antibody EGFRI for the treatment of mCRC within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer; Treatment with a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), Braftovi® (encorafenib), and Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer. Patients whose mCRC is being treated with a monoclonal antibody EGFRI in combination with a B-Raf inhibitor, such as Erbitux® (cetuximab) Injection in combination with Braftovi® (encorafenib) Capsules, will not be eligible to participate in this trial; Treatment with a systemic corticosteroid 14 days prior to Baseline or treatment with a topical corticosteroid to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0). Patients receiving systemic corticosteroids for 24 hours or less only at the time of chemotherapy infusions (for the prevention or treatment of chemotherapy-induced nausea and vomiting) will be allowed to enroll into this study; Treatment with a topical antibiotic to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0); Initiation of treatment with systemic antibiotic(s) < 28 days prior to Baseline (Day 0) or any change in dose or frequency of systemic antibiotic(s) within 28 days prior to Baseline. Patients that undergo a washout from systemic antibiotic(s) will be allowed to participate in this trial as long as no systemic antibiotics are taken within 7 days prior to Baseline and they meet all other eligibility criteria; Treatment with any other topical medication applied to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0). Treatment with an oral retinoid within 30 days or 5 half-lives of the drug prior to Baseline (Day 0), whichever is longer. Patients that undergo a washout from oral retinoids will be allowed to participate Treatment with another investigational drug within 30 days or 5 half-lives of drug prior to Screening, whichever is longer; Known hypersensitivity to the inactive ingredients of the study drug (active or placebo).
Facility Information:
Facility Name
Innovative Clinical Research Institute
City
Glendale
State/Province
California
ZIP/Postal Code
91204
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John Khoury, MD
Phone
562-693-4477
Email
KirstenBettino@theoncologyinstitute.com
Facility Name
UCLA
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zev Wainberg, MD
Phone
310-633-8400
Email
bcherian@mednet.ucla.edu
Facility Name
Miami Dermatology & Laser Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Reith
Phone
305-279-6060
Email
andream@miamidermlaser.com
Facility Name
Miami Dermatology and Laser Institute
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jill Waibel, MD
Phone
305-279-6060
Email
odalysf@miamidermlaser.com
Facility Name
Moffit Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Iman Imanirad
Phone
813-745-4673
Email
o'neke.nickle@moffitt.org
Facility Name
Appalachian Regional Healthcare
City
Hazard
State/Province
Kentucky
ZIP/Postal Code
41701
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samuel Bailey, MD
Phone
606-435-7202
Email
tmcdaniel@arh.org
Facility Name
Willis-Knighton Cancer Center
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anil Veluvolu, MD
Phone
318-212-8671
Email
fturner@wkhs.com
Facility Name
Dana Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole LeBoeuf, MD
Phone
617-732-4918
Email
Harita_Dharaneeswaran@dfci.harvard.edu
Facility Name
Hackensack Meridian Health
City
Neptune
State/Province
New Jersey
ZIP/Postal Code
07753
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Greenberg, MD
Phone
732-776-3301
Email
denise.theiler@hmhn.org
Facility Name
Memorial Sloane Kettering
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Lacouture, MD
Phone
646-608-2337
Email
KetosugK@mskcc.org
Facility Name
New York Cancer and Blood Specialists
City
New York
State/Province
New York
ZIP/Postal Code
11776
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard Zuniga
Phone
855-528-7322
Email
LCoolbaugh@nycancer.com
Facility Name
The Christ Hospital
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Starodub, MD
Phone
513-585-1140
Email
abby.reed@thechristhospital.com
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Efrat Dotan, MD
Phone
888-369-2427
Email
katrina.bynum@fccc.edu
Facility Name
UPMC Hillman Cancer Center Investigational Drug Service
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janie Zhang, MD
Phone
412-623-4891
Email
chrostowskim@upmc.edu
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anisha Patel, MD
Phone
713-745-1113
Email
jvleong@mdanderson.org
Facility Name
Providence Regional Cancer Partnership
City
Everett
State/Province
Washington
ZIP/Postal Code
98201
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meng Zhao, MD
Phone
425-297-5531
Email
roberta.lantzy@providence.org
Facility Name
MultiCare Institute for Research and Innovation
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abishek Marballi, MD
Phone
253-403-1677
Email
Samantha.Blake@multicare.org
Facility Name
Assuta Ashdod
City
Ashdod
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Larisa Ryvo, MD
Phone
972-72-3398279
Email
lironmao@assuta.co.il
Facility Name
E. Wolfson Medical Center
City
H̱olon
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ina Sarel
Phone
97235028813
Email
inasa@wmc.gov.il
Facility Name
Shaara Zedek Medical Center
City
Jerusalem
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ofer Purim
Phone
972-2-6555361
Email
shirlyad@szmc.org.il

12. IPD Sharing Statement

Learn more about this trial

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

We'll reach out to this number within 24 hrs